Latest Breaking News On - Eggan lab - Page 1 : vimarsana.com

QurAlis Receives Clinical Trial Authorisation (CTA) in the U K for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS).

United kingdomComunidad autonoma de catalunaAngela gengeKasper roetKevin egganHealthcare products regulatory agencyEuropean unionEggan labEuropean network to curePrnewswire quralis corporationAlis corporationClinical trial applicationTherapeutic sectionEuropean networkTrial authorisation

QurAlis FlexASOs Show High Potency and Improved Safety Over Standard ASOs

QurAlis FlexASOs Show High Potency and Improved Safety Over Standard ASOs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHarvard universityUnited kingdomQurali flexDaniel elbaumQurali flexasosKasper roetKevin egganCompany flexQuralis corporationEggan labHarvard medical schoolPrnewswire quralis corporationDevelopment of splice switching oligonucleotidesSplice modulator platformAnnual oligonucleotides

QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS).

United kingdomKasper roetKevin egganPrnewswire quralis corporationEuropean unionEggan labAlis corporationClinical trial regulationTrial authorisationClinical trial authorisation

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS).

United kingdomUnited statesSeanm healeyAngela gengeKevin egganDepartment of neurosciencesPrnewswire quralis corporationHospital centreHospital research centreUniversity of montrEggan labAlis corporationMerit cudkowiczMassachusetts general hospitalJulieanne dorn professorHarvard medical school

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

/PRNewswire/ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS).

United kingdomKasper roetKevin egganHospital centreHospital research centreUniversity of montrHealth canadaEggan labDepartment of neurosciencesPrnewswire quralis corporationAlis corporation